Evidence map›Paper›PMID 40524238›Full record

ArticleCancer & metabolism2025

Can serum metabolic signatures inform on the relationship between healthy lifestyle and colon cancer risk?

Komodo Matta, Vivian Viallon, Anastasia Chrysovalantou Chatziioannou, Nivonirina Robinot, Roland Wedekind, Christina C Dahm, Agnetha Linn Rostgaard-Hansen, Anne Tjønneland, Therese Truong, Chloé Marques and 28 more

Abstract read
In one paragraph

Article in Cancer & metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. NADAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

Komodo MattaInternational Agency for Research On Cancer (IARC/WHO), Lyon, France. mattak@iarc.who.int.
Vivian ViallonInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Anastasia Chrysovalantou ChatziioannouInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Nivonirina RobinotInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Roland WedekindInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Christina C DahmDepartment of Public Health, Aarhus University, Bartholins Alle 2, Aarhus C, 8000, Denmark.
Agnetha Linn Rostgaard-HansenThe Danish Cancer Institute, Strandboulevarden 49, Copenhagen, 2100, Denmark.
Anne TjønnelandThe Danish Cancer Institute, Strandboulevarden 49, Copenhagen, 2100, Denmark.
Therese TruongParis-Saclay University, UVSQ, Gustave Roussy, CESP, Inserm, Villejuif, France.
Chloé MarquesParis-Saclay University, UVSQ, Gustave Roussy, CESP, Inserm, Villejuif, France.
Pauline FrenoyParis-Saclay University, UVSQ, Gustave Roussy, CESP, Inserm, Villejuif, France.
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Renée Turzanski FortnerDivision of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Matthias B SchulzeDepartment of Molecular Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
Sabrina SieriEpidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale Dei Tumori Di Milano Via Venezian, Milan, 20133, Italy.
Mario FordelloneUnit of Medical Statistics, University of Naples "Vanvitelli", Naples, Italy.
Rosario TuminoHyblean Association For Epidemiology Research, AIRE-ONLUS, Ragusa, Italy.
Fulvio RicceriDepartment of Clinical and Biological Sciences, Centre for Biostatistics, Epidemiology, and Public Health (C-BEPH), University of Turin, Turin, Italy.
Tonje BraatenDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Therese Haugdahl NøstDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Maria-Jose SánchezEscuela Andaluza de Salud Pública (EASP), Granada, 18011, Spain.
Olatz Mokoroa-CarolloSub Directorate for Public Health and Addictions of Gipuzkoa, Ministry of Health of the Basque Government, San Sebastian, Spain.
Sandra Colorado-YoharCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, 28029, Spain.
Camino Trobajo-SanmartínCentro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), Madrid, 28029, Spain.
Keren PapierDepartment of Population Health, Cancer Epidemiology Unit, Nuffield, University of Oxford, Oxford, UK.
Rhea HarewoodDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Kostas TsilidisDepartment of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
Salvatore VaccarellaInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Mattias JohanssonInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Elisabete WeiderpassInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Cyrille DelpierreCenter for Epidemiology and Research in POPulation Health (CERPOP), Inserm, Université de Toulouse III, Toulouse, France.
Sebastien LamyInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Kristin Benjaminsen BorchDepartment of Community Medicine, Faculty of Health Sciences, UiT The Arctic University of Norway, Tromsø, Norway.
Pekka Keski-RahkonenInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Elio RiboliDepartment of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College London, London, UK.
Heinz FreislingInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Marc GunterInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.
Pietro FerrariInternational Agency for Research On Cancer (IARC/WHO), Lyon, France.

Funding

World Cancer Research Fund IIG_FULL_2022_025World Health Organization 001
6 · The paper itself

Abstract

backgroundColon cancer is strongly influenced by lifestyle factors. Sociodemographic factors like sex and socioeconomic position (SEP) might modulate the relationship between lifestyle and colon cancer risk. Metabolomics offers potential to uncover biological mechanisms linking lifestyle and colon cancer.

methodsLifestyle and untargeted metabolomic data were available from a nested case-control study within the European Prospective Investigation into Cancer and Nutrition (EPIC), including 1,067 colon cancer cases and 1,067 controls matched on age, sex, study centre, and blood collection time. Serum samples were analyzed using liquid chromatography-mass spectrometry. The Healthy Lifestyle Index (HLI) score was derived from smoking habits, alcohol intake, body mass index (BMI), physical activity, and diet. Penalised regression was applied in controls to derive metabolic signatures for the HLI and the lifestyle components. Associations of lifestyle factors and the metabolic signatures with colon cancer risk were estimated in conditional logistic regression models, overall and by sex and SEP.

resultsThe HLI score was inversely associated with colon cancer risk, with an odds ratio (OR) per 1-standard deviation (SD) increment equal to 0.79; 95% CI: 0.71, 0.87. The metabolic signature of HLI, comprising 130 features, was moderately correlated with HLI (r = 0.59; 94% CI: 0.56, 0.61), and was inversely associated with colon cancer risk (OR = 0.86; 95% CI: 0.78, 0.95). After adjustment for the HLI score, the association of the metabolic signature of HLI and colon cancer risk was null (OR = 1.00, 95% CI 0.88, 1.13). Associations of lifestyle factors and the metabolic signature with colon cancer risk were consistently stronger for men than for women and did not differ by SEP.

conclusionsIn this study across seven European countries, healthy lifestyle was inversely associated with colon cancer risk, with stronger associations in men than women and no differences across SEP. However, the serum metabolic signatures after adjustment for lifestyle factors were not found to be associated with colon cancer risk, suggesting that lifestyle impacts colon cancer through mechanisms not captured by the signatures.

Indexed as

Colon cancerHealthy LifestyleLASSO regressionSexSocioeconomic positionUntargeted metabolomics

Identifiers

PMID40524238
PMCPMC12168339

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.